1. Home
  2. DCBO vs AKBA Comparison

DCBO vs AKBA Comparison

Compare DCBO & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCBO
  • AKBA
  • Stock Information
  • Founded
  • DCBO 2016
  • AKBA 2007
  • Country
  • DCBO Canada
  • AKBA United States
  • Employees
  • DCBO N/A
  • AKBA N/A
  • Industry
  • DCBO
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • DCBO
  • AKBA Health Care
  • Exchange
  • DCBO Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • DCBO 788.2M
  • AKBA 861.7M
  • IPO Year
  • DCBO 2020
  • AKBA 2014
  • Fundamental
  • Price
  • DCBO $27.33
  • AKBA $2.94
  • Analyst Decision
  • DCBO Strong Buy
  • AKBA Strong Buy
  • Analyst Count
  • DCBO 6
  • AKBA 5
  • Target Price
  • DCBO $41.33
  • AKBA $6.90
  • AVG Volume (30 Days)
  • DCBO 59.1K
  • AKBA 2.9M
  • Earning Date
  • DCBO 11-07-2025
  • AKBA 11-06-2025
  • Dividend Yield
  • DCBO N/A
  • AKBA N/A
  • EPS Growth
  • DCBO 33.51
  • AKBA N/A
  • EPS
  • DCBO 0.69
  • AKBA N/A
  • Revenue
  • DCBO $230,502,000.00
  • AKBA $203,733,000.00
  • Revenue This Year
  • DCBO $13.02
  • AKBA $43.91
  • Revenue Next Year
  • DCBO $8.37
  • AKBA $32.09
  • P/E Ratio
  • DCBO $39.36
  • AKBA N/A
  • Revenue Growth
  • DCBO 15.11
  • AKBA 16.75
  • 52 Week Low
  • DCBO $25.50
  • AKBA $1.26
  • 52 Week High
  • DCBO $53.86
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • DCBO 33.68
  • AKBA 51.11
  • Support Level
  • DCBO $26.95
  • AKBA $2.66
  • Resistance Level
  • DCBO $28.03
  • AKBA $3.01
  • Average True Range (ATR)
  • DCBO 0.60
  • AKBA 0.12
  • MACD
  • DCBO -0.18
  • AKBA 0.04
  • Stochastic Oscillator
  • DCBO 11.05
  • AKBA 77.14

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: